Adalimumab therapy in hepatitis B virus-negative polyarteritis nodosa
A case report

Chrong-Reen Wang, MD, PhD\textsuperscript{a,*}, Chao-Chun Yang, MD, PhD\textsuperscript{b}

Abstract

Introduction: Polyarteritis nodosa (PAN) is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such patients with a treatment failure or the disease relapse.

Case presentation: We report a 42-year-old male Han Chinese who received adalimumab (ADA) alone during his vasculitis relapse, manifesting with weight loss, ankle arthritis, testicular inflammation and new-onset hypertension. Under the ADA 40 mg biweekly subcutaneous injection, there were the disappearance of clinical activity and no disease flares with a follow-up period of 26 months.

Conclusion: The clinical observation in this patient suggests a potential efficacy of ADA therapy in controlling the disease activity of PAN.

Abbreviations: ADA = adalimumab, ANCA = antineutrophil cytoplasmic antibody, BVAS = Birmingham Vasculitis Activity Score, FFS = five-factor score, IFX = infliximab, mAb = monoclonal antibody, PAN = polyarteritis nodosa, PSV = primary systemic vasculitis.

Keywords: adalimumab, five-factor score, polyarteritis nodosa, TNF mAb

1. Introduction

Polyarteritis nodosa (PAN) is a rare form of primary systemic vasculitis (PSV) predominantly targeting medium- or small-sized arteries and not associated with anti-neutrophil cytoplasmic antibody (ANCA).\textsuperscript{1,2} Although the natural untreated course of this disease is rapidly progressive with a fatal outcome, the introduction of corticosteroids has brought about an improved survival.\textsuperscript{3} Based on a five-factor score (FFS) developed by the French Vasculitis Study Group as a prognostic tool, current therapeutic approach in PAN considers corticosteroids alone in those without FFS and the addition of cyclophosphamide in the presence of critical organ involvement including renal, gastrointestinal and cardiac manifestations.\textsuperscript{2,3} Biologic agents are prescribed in PSV with a treatment failure or the disease relapse.\textsuperscript{4,3} In the PAN pathogenesis, activated endothelial cells, resulting from the TNF stimulation, can perpetuate and potentiate the inflammatory milieu through the production of pro-inflammatory cytokines.\textsuperscript{2,6} Herein, we reported a PAN patient who received adalimumab (ADA), a TNF monoclonal antibody (mAb), during his vasculitis relapse, resulting in the disappearance of clinical activity and no disease flares with a follow-up period of 26 months.

2. Case presentation

A 42-year-old male Han Chinese visited the dermatological clinic of National Cheng Kung University Hospital with a 6-month history of purpuric reticulate erythema and nodules over the lower extremities in August 2012. Biopsy of a nodule revealed dense infiltrates consisting of abundant neutrophils and lymphocytes around the subcutaneous small artery with neutrophilic fibrin-platelet thrombus in the lumen (Fig. 1), consistent with the histopathological findings of PAN. Weight loss, diffuse myalgia, ankle arthralgia, and testicular pain were also noted, and he was referred to the rheumatological clinic. On physical examinations, he had swollen ankle joints and enlarged right testis with induration. Laboratory tests showed elevated ESR and CRP values, unremarkable hemogram data, normal creatinine levels, and no significant abnormalities on urinalysis. Autoantibodies were not identified, including ANCA, antinuclear antibody, lupus anticoagulant and rheumatoid factor. Hepatitis B and C viral markers were absent. There were no abnormal findings on chest x-ray, electrocardiogram, abdominal and cardiac echography. High-dose corticosteroids (1 mg/kg/day prednisolone) were prescribed under the diagnosis of PAN, fulfilling the 2012 updated Chapel Hill consensus definitions.\textsuperscript{11} In the clinical remission, prednisolone dosages were tapered down and replaced by azathioprine (2 mg/kg/day). Nevertheless, he had a relapsing event with recurrent weight loss, right ankle swelling and right testicular pain as well as new-onset hypertension controlled by...
The effect of ADA therapy in controlling the disease activity of PAN. Despite the clinical observation in 1 patient, it suggests a potential role in PAN. Collectively, there were recurrent disease activities with ankle arthritis, proteinuria or hematuria, normal creatinine levels and negative findings on renal angiography. Since the patient had no previous history of corticosteroids due to associated side effects in the previous usage, ADA 40 mg biweekly subcutaneous injection was prescribed again with improvement of arthritis and skin lesions. Currently, this prednisolone dosages are gradually decreased with the addition of weekly methotrexate up to 25 mg. Indeed, cyclophosphamide usage can be considered for hist-PAN-associated neuropathy during the subsequent follow-up.

3. Discussion

Owing to the absence of visceral involvement at the disease onset, high-dose corticosteroids were prescribed as the first-line therapy in this patient. Anti-TNF mAb was used as an alternative therapeutic option. In a relapsing episode with a Birmingham Vasculitis Activity Score (BVAS) up to 9, leading to the disappearance of clinical manifestations and no disease flares in a 26-month follow-up course. However, upon discontinuing its usage, there were recurrent disease activities with ankle arthritis, skin lesions and peripheral neuropathy (BVAS 13). Collectively, despite the clinical observation in 1 patient, it suggests a potential effect of ADA therapy in controlling the disease activity of PAN.

In spite of no fully validated efficacy of TNF blockades on the PAN therapy, such an agent was chosen in the reported case due to lack of autoantibodies and no hepatitis B virus infection. Interestingly, significantly decreased BVAS is observed in a pediatric series with 8 cases on the infliximab (IFX) therapy.[8] For the adult-onset patients, successful experience has been reported from one with etanercept injection and 4 receiving IFX infusion including 2 with gastrointestinal or renal involvement.[9-11] Indeed, the potential of TNF antagonists can be further realized with large-scale randomized trials to ascertain therapeutic regimens and clinical benefits in PAN, a difficult-to-treat rheumatology disorder.

4. Conclusions

PAN is a difficult-to-treat rheumatology disorder, and biologic agents have been used in such cases with a treatment failure or the disease relapse. We report a male patient who received ADA therapy alone during his vasculitis relapse, resulting in the disappearance of clinical activity and no disease flares with a follow-up period of 26 months.

Acknowledgment

The authors are indebted to Prof. Julia Yu-Yun Lee and other physicians as well as nurses involved in the diagnosis and management of the reported case at the National Cheng Kung University Hospital.

Author contributions

Conceptualization: Chrong-Reen Wang.
Data curation: Chrong-Reen Wang, Chao-Chun Yang.
Formal analysis: Chrong-Reen Wang.
Investigation: Chrong-Reen Wang, Chao-Chun Yang.
Validation: Chrong-Reen Wang.
Writing – original draft: Chrong-Reen Wang.
Writing – review & editing: Chrong-Reen Wang.

References

[1] Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–1.
[2] De Virgilio A, Greco A, Magliulo G, et al. Polymyalgia nodosa: a contemporary overview. Autoimmun Rev 2016;15:564–70.
[3] Guillemin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 2011;90:19–27.
[4] Eleftheriou D, Melo M, Marks SD, et al. Biologic therapy in primary systemic vasculitis of the young. Rheumatology 2009;48:978–86.
[5] Silva-Fernández I, Loza E, Martínez-Taboada VM, et al. Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum 2014;43:542–57.
[6] Pall AA, Savage CO. Mechanisms of endothelial cell injury in vasculitis. Springer Semin Immunopathol 1994;16:23–37.
[7] Imboden JB. Involvement of the peripheral nervous system in polyarteritis nodosa and antineutrophil cytoplasmic antibodies-associated vasculitis. Rheum Dis Clin North Am 2017;43:633–9.
[8] Luqmani RA, Bacon PA, Moores RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotising vasculitis. QJM 1994;87:671–8.
[9] García-Porrua C, Gonzalez-Gay MA. Successful response to infliximab in a patient with undifferentiated spondyloarthritis coexisting with polyarteritis nodosa-like cutaneous vasculitis. Clin Exp Rheumatol 2003;21:5138.
[10] Wu K, Throssell D. A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 2006;21:1710–20.
[11] Al-Bishri J, de Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2003;30:1371–3.
[12] Zoshima T, Matsumura M, Suzuki Y, et al. A case of refractory cutaneous polyarteritis nodosa in a patient with hepatitis B carrier status successfully treated with tumor necrosis factor alpha blockade. Mod Rheumatol 2013;23:1029–33.
[13] Matsuo S, Hayashi K, Morimoto E, et al. The successful treatment of refractory polyarteritis nodosa using infliximab. Intern Med 2017;56:1435–8.